Aarhus, Denmark (UroToday.com) Dr. Bernard-Pierrot from the Institut-Curie in Paris presented data investigating genetic alterations that explained the role of peroxisome proliferator-activated receptor gamma (PPARG) activation in luminal muscle-invasive bladder cancer (MIBC). PPARG was sequenced in 384 bladder tumors (institutional cohort) and identified in a publicly available cohort of 455 MIBC cases. Recurrent mutations of PPARG appeared to confer PPARG-dependency and tumorogenicity through the PPARG/RXRA pathway activation in luminal bladder cancers. Non-recurrent mutations were associated with basal tumors. Dr. Bernard-Pierrot concluded that this dual subtype-dependent role of PPARG in bladder cancer underscored the importance of molecular subtyping in understanding the pathophysiology of MIBC.

pparg and rxra mutations

Take-home message:

  • Recurrent mutations in PPARG were associated with luminal bladder cancers, along with increased tumorigenicity through the PPARG/RXRA pathway, while non-recurrent mutations of PPARG were associated with basal tumors

Presented by: Isabelle Bernard-Pierrot, PhD, Researcher Centre de recherche de l’Institut Curie, Paris, France

Written by: Dr. Vikram M. Narayan (@VikramNarayan), Urologic Oncology Fellow with Ashish M. Kamat, MD (@UroDocAsh), Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX at the 17th meeting of the International Bladder Cancer Network, (IBCN, #IBCN2019) October 3rd – 5th, 2019 in Aarhus, Denmark.